Webinars


Welcome to the MTPConnect Webinar page.

View all our on-demand webinars below.


WA MTP Sector Spotlight Series: Recce Pharmaceuticals

  • 16 November 2022

About this event

Our monthly breakfast series is an opportunity for representatives from across the MTP sector to connect, collaborate and learn about upcoming opportunities, and hear the stories and successes of WA organisations developing health and medical innovations. Join us over a light breakfast each month at the Harry Perkins Institute of Medical Research.

Featuring Recce Pharmaceuticals

Recce Pharmaceuticals (ASX: RCE) is an ASX listed pharmaceuticals company pioneering the development and commercialisation of a New Class of Synthetic Anti-Infectives designed to address the urgent global health threat posed by antibiotic-resistant superbugs and emerging viral pathogens.

Recce’s anti-infective pipeline is comprised of broad-spectrum synthetic antibiotics, RECCE® 327 and RECCE® 435, and a synthetic anti-viral, RECCE® 529. Recce’s compounds, respectively, contain unique mechanisms of action against hypermutation on bacteria and viruses.

Join Recce’s CEO James Graham and CSO Michele Dilizia alongside MTPConnect’s Dr Tracey Wilkinson to discuss the development and commercialisation of anti-infectives, the regulatory pathway for antibiotics and the future of antimicrobial resistance.

About our speakers

James Graham

Mr Graham is the Chief Executive Officer of Recce Pharmaceuticals. Mr Graham was former Executive Director and has extensive experience in marketing, business development and commercialisation of early-stage technologies with global potential. Mr Graham has served on Recce’s Board of Directors for six years with a focus on expanding Recce’s commercial opportunities and clinical initiatives.

Michele Dilizia

Ms Dilizia is the Chief Scientific Officer of Recce Pharmaceuticals and is a qualified Medical Scientist with a specialisation in medical microbiology. Ms Dilizia successfully co-led the research and development of Recce’s suite of anti-infective compounds, resulting in a portfolio of granted patents across the globe, including a Qualified Infectious Disease Product designation with the U.S. Food and Drug Administration (FDA).


WA MTP Sector Spotlight Series: Singular Health Group

  • 07 October 2022

The MTPConnect WA Life Sciences Innovation Hub invites you to join the monthly WA MTP Sector Spotlight Series event.

About this event

Our monthly breakfast series is an opportunity for representatives from across the MTP sector to connect, collaborate and learn about upcoming opportunities, and hear the stories and successes of WA organisations developing health and medical innovations. Join us over a light breakfast in the last week of each month at the Harry Perkins Institute of Medical Research.

Featuring Singular Health Group Ltd

Singular Health Group is an ASX-listed medical technology company improving patient education and enabling patient-specific surgeries.

Singular Health has developed a proprietary Volumetric Rendering Platform (VRP) that leverages existing 2D radiological images to generate fully-immersive patient-specific 3D/VR models.

Complementing its VRP technology, Singular Health has developed a Virtual Surgical Planning and Design software and has invested in a 25% stake in medical-grade 3D printing company Additive Engineering. These investments and developments represent key milestones in Singular Health’s efforts to commercialise its ‘Scan to Surgery’ initiative, a world-first vertically integrated platform that revolutionises the planning and execution of personalised surgical procedures.

With Singular Health, practitioners are empowered by having the ability to collaborate with manufacturers of patient-specific medical components in real-time, while patients benefit from having access to easily comprehensible and enhanced medical information.

Visit the events page for more information.



WA MTP Sector Spotlight Series: AIQ Solutions

  • 07 October 2022

The MTPConnect WA Life Sciences Innovation Hub invites you to join the monthly WA MTP Sector Spotlight Series event.

Our monthly breakfast series is an opportunity for representatives from across the MTP sector to connect, collaborate and learn about upcoming opportunities, and hear the stories and successes of WA organisations developing health and medical innovations. Join us over a light breakfast in the last week of each month at the Harry Perkins Institute of Medical Research.

Join President and CEO Eric Horler in conversation with Dr Tracey Wilkinson for a fireside chat discussing the AIQ story, including creating a startup out of a University project and raising private equity money in a Series A, using AI in nuclear medicine and oncology to assess the efficacy of treatments and provide cancer patients with a prognosis, and why a startup in Wisconsin came all the way to Perth to set up its only other office.

Visit the events page for more information. 



CTCM Information Session: Funding call for Medical Devices - Round 2

  • 25 August 2022

The Clinical Translation and Commercialisation - Medtech (CTCM) program, delivered by MTPConnect, is offered under the 2020 Early Stage Translation and Commercialisation Support Grant of the Medical Research Future Fund's Medical Research Commercialisation Initiative.

The $19.75 million program will identify and nurture high-quality medical device projects that have commercial potential and support their translation through early clinical trials. The program is focused on Australian small to medium-sized enterprises (SMEs) and aims to boost commercialisation of home-grown medical products.

The CTCM program will be calling for round two Expressions of Interest (EOI) to fund eligible Australian small to medium-sized enterprises (SMEs) to boost commercialisation of home-grown medical products. CTCM projects will be funded for between $250,000-$1,500,000 for a maximum of 24 months.

Eligible applications must include some level of innovation in hardware (proposals relating to pure software as a medical device (SaMD) are ineligible). To be eligible, applicants are required to provide a co-contribution dependent on the total CTCM funding requested.

Hear from Dr Duncan Macinnis, MTPConnect Director Stakeholder Engagement NSW & ACT, and CTCM Program partners:

  • MTAA - CTCM Program Manager, Stuart Anderson
  • MDPP - MedTech Ventures Case Manager, Dr Andrew Milligan 
  • Cicada Innovations - Head of Technology, Hebbat Manhy

For further information and guidelines on how to apply, visit CTCM Program Round 2

Applications for CTCM Round 2 funding will open on Friday 9 September 2022 and close on Friday 7 October 2022 at 16:00 AEDT.

Download webinar slides



CTCM Information Session: Funding call for Medical Devices - Round 1

  • 03 February 2022

The Clinical Translation and Commercialisation - Medtech (CTCM) program, delivered by MTPConnect, is offered under the 2020 Early Stage Translation and Commercialisation Support Grant of the Medical Research Future Fund's Medical Research Commercialisation Initiative.

The $19.75 million program will identify and nurture high-quality medical device projects that have commercial potential and support their translation through early clinical trials. The program is focused on Australian small to medium-sized enterprises (SMEs) and aims to boost commercialisation of home-grown medical products.

The CTCM program is now calling for round one Expressions of Interest (EOI) to fund eligible Australian small to medium-sized enterprises (SMEs) to boost commercialisation of home-grown medical products. CTCM projects will be funded for between $250,000-$1,500,000 for a maximum of 24 months. Applicants will also be required to provide a cash co-contribution to the value of 50 percent of the CTCM funding request to be eligible.

Hear from Dr Duncan Macinnis, MTPConnect Director Stakeholder Engagement NSW & ACT, and CTCM Program partners:

  • MTAA - Chief Executive Officer, Ian Burgess
  • MDPP - MedTech Ventures Case Manager, Dr Andrew Milligan 
  • Cicada Innovations - Head of Medtech & Biotech, Dr Dharmica Mistry

For further information and guidelines on how to apply, visit CTCM Program Round 1. Applications close Friday 11 March 2022, 4:00pm AEDT.

Download webinar slides


REDI Information Session: Call for Proposals for Skills Gap Programs (Round 3)

  • 21 October 2021

Through the $32 million Researcher Exchange & Development (REDI) initiative supported by the MRFF, MTPConnect is partnering with research, training & industry organisations to deploy an integrated three-pillar plan driving skills & workforce development for the medical technology, biotechnology & pharmaceutical (MTP) sector nationally. The REDI program has undertaken skills gap analysis research in the MTP sector and recently released a third Skills Gap report titled “Positioning the MTP workforce for post-pandemic prosperity”. Closing skills gaps identified in this research is vital to power the next wave of innovation and growth for Australia.

Under Round 3 of the REDI Contestable (REDIC) Program, MTPConnect is calling for suitably qualified organisations to submit proposals for programs that address five key skills gaps. 

Hear from MTPConnect Senior Director Stakeholder Engagement & REDI Co-chair, Dr Rebecca Tunstall, and the REDI team of Jarrod Belcher and Dr Michelle Low.

For more information and guidelines on how to apply, visit the REDI Contestable Program page. Applications close 30 November 2021 at 5:00pm AEDT


TTRA Info Session: Funding call for Diabetes & Cardiovascular Disease Research Projects (Round 2)

  • 13 October 2021

MTPConnect is delivering the $47 million Targeted Translation Research Accelerator (TTRA) initiative for diabetes and cardiovascular disease, supported by the MRFF. The TTRA is providing a new integrated research program to improve the prevention, diagnosis, treatment and management of diabetes and cardiovascular disease (D&CVD) in Australia. The TTRA is now calling for Expressions of Interest (EOI) via the second round of the Research Projects opportunity, to fund eligible organisations in developing innovative digital health solutions, medical devices, therapeutics and behavioural interventions for D&CVD. 

IMPORTANT
- Submissions now close at 16:00 AEDT on Thursday 25 November 2021 (DEADLINE EXTENDED - announced 28 October).

Hear from MTPConnect's:
• Managing Director & CEO - Dr Dan Grant
• Senior Director TTRA Program - Lauren Kelly
• Director TTRA Program - Dr Mana Liao
• Project Manager TTRA Program - Dr Erin McAllum

You'll also hear from the TTRA Partners:
• ANDHealth's Chief Product Officer & Co-Founder - Grace Lethlean
• MDPP's National Program Manager - Olivia White
• UniQuest's Project Manager, TTRA Program - Dr Leigh Ford

PLEASE NOTE: The webinar slides and transcript are available for download.


Launching an updated report on 'Australia's Clinical Trials Sector'

  • 20 May 2021

MTPConnect marked International Clinical Trials Day 2021 with the release of a new report that reveals the size and scope of Australia’s clinical trials sector and opportunities for future growth.

The report 'Australia’s Clinical Trials Sector: Advancing innovative healthcare and powering economic growth' has been developed in partnership with L.E.K Consulting and will provide an essential reference for the sector.

Hear insights from our esteemed panel:

  • Dr Dan Grant, Managing Director & CEO @ MTPConnect
  • Dr Rebecca Tunstall, Senior Director Stakeholder Engagement @ MTPConnect
  • Carrie Bloomfield, Co-Chair @ R&D Taskforce, and Director Clinical Operations @ GlaxoSmithKline Australia
  • Dr Janelle Bowden, Managing Director @AccessCR
  • Dr Megan Robertson, Group Chief Research Officer @St Vincent’s Health Australia, and Chair @ AusBiotech Clinical Trial Advisory Group
  • Prof John Zalcberg, Board Chair @ ACTA, and Head, Cancer Research Program @ Monash University

Download the report at www.mtpconnect.org.au/reports.


Adaptive regulation for digital health technologies - A pathway for industry

  • 24 March 2021

MTPConnect is pleased to bring you our March seminar series webinar - “Adaptive regulation for digital health technologies - a pathway for industry” - on 24 March 2021. Digital health technologies (DHTs) have the potential to disrupt both the medical technology, biotechnology and pharmaceutical sector and the broader delivery of healthcare, creating challenges for the effective and timely regulation of new therapeutic goods.

Speakers:

  • Dr Lisette Pregelj - the University of Queensland
  • Helen Souris - Cardihab
  • Tracey Duffy - Therapeutic Goods Administration
  • Dr Rob Grenfell - CSIRO
  • Bronwyn Le Grice - ANDHealth


REDI Information Session: Call for Proposals for Skills Gap Programs (Round 2)

  • 17 March 2021

MTPConnect deploys the $32 million Researcher Exchange and Development (REDI) initiative supported by the MRFF. The four-year initiative aims to deliver system-wide improvements to skills development and training programs for the MTP workforce.

Under Round Two of the REDI Contestable (REDIC) Program, MTPConnect is calling for suitably qualified organisations to submit proposals for programs that address two key skills gaps:

  • Identifying unmet market need and understanding the clinical context
  • Ability to secure investment, funding and/or industry collaboration

For more information and guidelines on how to apply, visit the REDI Contestable Program page.


Collaboration for Innovation: CRC-P Grants for Medical Product Manufacturing Webinar

  • 24 February 2021

MTPConnect is pleased to bring you our first seminar series webinar for 2021 in conjunction with BioMelbourne Network.

This seminar will highlight the opportunity to access Round 11 of Cooperative Research Centres Projects (CRC-P) Grants that provide funding for short-term industry-led research collaborations to support manufacturing-related projects in the MTP sector. Round 11 also includes dedicated funding for projects that support research and development activities in regional areas.

Discussions will centre on the Modern Manufacturing Strategy and the advanced manufacturing of medical products (therapeutics, devices, diagnostics), as it relates to value creation.


TTRA Research Centres Information Session

  • 20 January 2021

The Targeted Translation Research Accelerator (TTRA) initiative, a Medical Research Future Fund initiative delivered by MTPConnect, is rolling out a $38 million funding opportunity to improve the prevention, diagnosis, management and treatment of diabetes, cardiovascular disease and their related complications in Australia. To stimulate collaboration across industry, research and clinical organisations, we’re allocating $20 million to support the establishment of two new Research Centres; one focused on diabetes-associated complications and the other on cardiovascular disease-associated complications and each funded for up to $10 million over four years. Applications are now open for Expressions of Interest for these two new Research Centres, and close at 16:00 AEDT on 15 March 2021.


TTRA Research Projects Information Session

  • 19 January 2021

The Targeted Translation Research Accelerator (TTRA) initiative for diabetes and cardiovascular disease is calling for Expressions of Interest (EOI) for the first round of Research Projects funding. We’re making available $18 million to support translational Research Projects that have the potential to transform diabetes and cardiovascular disease outcomes and reduce the burden of disease on patients, families and the community – with up to $6 million available in this first round.

Applications close at 16:00 AEDT on 22 February 2021.


REDI Information Session - Call for Fellowships Applications from Industry Sponsors

  • 17 December 2020

IMPORTANT UPDATE: On 8 October 2021 MTPConnect announced that the REDI Fellowships eligibility had expanded to smaller companies. Therefore this webinar recording from 17 December 2020 should be viewed with this in mind. Please see the website for current guidelines and further information.

.........

MTPConnect operates the $32 million Researcher Exchange and Development within Industry (REDI) program supported by the MRFF. The four-year initiative is delivering system-wide improvements to skills development and training programs for the medical technology, biotechnology and pharmaceutical (MTP) sector workforce.

The REDI Fellowship Program can provide up to $250,000 per Fellow, per annum, for up to 40 industry Fellowships giving Australian MTP companies the financial support to bring academics and clinicians in-house for up to twelve months to work on priority medical research projects. The program is an open call.


Show Me The Money: Preparing Successful Commercialisation Funding Applications. Listen to Our Webinar!

  • 18 November 2020

We’re patching you into our November 2020 Seminar Series webinar about how to craft a successful commercialisation funding application. Hear valuable tips from communications specialist and grant writer Rebecca Colless from gemaker, experienced grant assessor Dr Andy Gearing from BioComm Squared and Professor Kevin Pfleger from UWA who shares his academic and commercial experience, highlighting key differences between research and commercialisation applications. MTPConnect’s Dr Dan Grant brings insights from his own research career and administering MTPConnect’s multiple translation funding programs. They explore the steps to developing a well-executed application, share their experiences and reveal why it is so important to get the story right. The session was led by MTPConnect’s Director of Stakeholder Engagement for WA Dr Tracey Wilkinson. This episode will be of interest to researchers, research offices, start-ups & SMEs.


REDI Information Session: Call for Proposals for Skills Gap Training Programs

  • 19 November 2020

In delivering the REDI program, MTPConnect is partnering with research, training and industry organisations to deploy an integrated three-pillar plan driving skills and workforce development for the MTP sector nationally.

Our REDI initiative has undertaken a medtech & pharma Industry skills gap analysis and identified several critical skills gaps that inhibit the industry maximising the impact on healthcare in Australia. The call for proposals for REDI Pillar 2 Round One for ‘urgent skills gap training courses/programs’ close at 17.00hrs (AEDT) on Tuesday, 15 December 2020.


Why Australia is the Destination of Choice for International Medical Device Clinical Trials

  • 06 October 2020

To mark our involvement in the Virtual MedTech Conference 2020 in Toronto, we hosted a special webinar with Austrade, for US and Canadian medical device companies who may benefit from running clinical trials in Australia. The session explored ‘Australia as a medical device trial destination: Maintain momentum in your clinical development program’, and focused on first-in-human / early phase cardiovascular medical device trials. Discussions cover the clinical trials landscape in Australia and the impact of COVID-19 on maintaining research momentum, the opportunities for international collaboration and a German company’s firsthand experience as a multinational medical device company running clinical trial programs in Australia.

A special thanks to our stellar panel:

  • Hon. Peter McGauran – Australia’s Consul General and Senior Trade & Investment Commissioner, Austrade Houston
  • Dr Dan Grant – Managing Director & CEO, MTPConnect
  • Prof John Kovacic – Executive Director, Victor Chang Cardiac Research Institute
  • Prof Gemma Figtree – President, Australian Cardiovascular Alliance
  • Mr Falko Thiele – Director Clinical & Regulatory Affairs, BIOTRONIK Australia (HQ Germany)


How is MedTech Innovation Pushing the Frontiers of Human Movement? Listen to our Webinar!

  • 30 July 2020

We’re patching you in to our July webinar in the 2020 Seminar Series. Hear from A/Prof Jacqueline Alderson from UWA in Perth, Rick Wingfield from Catapult Sports in Melbourne, Dr Lee Walsh from Platypus Technical in Canberra and Dr Dan Grant from MTPConnect in Melbourne, as they discuss this emerging Knowledge Priority - biomechanics & human movement - and the growth of digital technologies creating a revolution in the field of sports science and biomechanics that could impact wellbeing, physical performance and healthy ageing. The panel discuss the latest developments in wearable sensors, data analytics and the ‘cool tech’ that is being trialled and tested in Australia in high performance sporting codes like motorsport, soccer, football and rugby. The challenges of validation and regulatory approvals were covered. There are also some interesting career opportunities opening up in sports science for engineers, data and computer scientists. 


Are You Exploring Pathways To Commercialise a Health Innovation Webinar

  • 30 June 2020

Hear from Boston-based CIMIT Chief Operating Officer Dr John Collins, Health Horizon Co-Founder & CEO Marcus Dawe and OncoRes Medical MD & CEO Dr Kath Giles to discuss how to best to navigate the pathways to commercialising health innovations. The team guided by our Senior Director Stakeholder Engagement Dr Rebecca Tunstall as MC, along with MTPConnect’s MD & CEO Dr Dan Grant, heard about the journey of OncoRes Medical developing introperative imaging technology to improve accuracy of breast cancer surgery. CIMIT’s GAITS model was showcased as a tool to help innovators map their commercialisation process to get their solutions to patients faster. And one of Australia’s latest health innovations, the Health Horizon platform, revealed how it keeps track of health innovations around the world for innovators, funders and the public so everyone can follow the progress of medical breakthroughs.